The Ministry of Health and Welfare in Taiwan notified that the renaming of Microbio’s new drug “Chemo young” to “MICRSOY” has been approved.

2.Company name:Microbio Co., LTD.

3.Relationship to the Company (please enter ”head office” or

”subsidiaries”):head office

4.Reciprocal shareholding ratios:NA

5.Cause of occurrence:

”Chemo young” oral solution is a Symbiota product developed through Microbio’s

proprietary platform for anaerobic symbiotic fermentation of gut bacteria. It was

approved as the first oral new drug under Chinese medicine category for alleviating

chemotherapy-induced fatigue and loss of appetite in cancer patients. This drug has

treated and mitigated other diseases after its launch, demonstrating its potential in

developing new indications, therefore, a renaming to ”MICRSOY” oral solution has

been applied.

6.Countermeasures:None

7.Any other matters that need to be specified(the information

disclosure also meets the requirements of Article 7, subparagraph 9

of the Securities and Exchange Act Enforcement Rules, which brings

forth a significant impact on shareholders rights or the price of

the securities on public companies.):

(1) Microbio’s Symbiota is a Postbiotics product meticulously developed by cutting-edge

techniques, and the current Symbiota portfolio achieved U.S. independent/self-affirmed

GRAS (Generally Recognized As Safe) conclusion this July, which includes ”MICRSOY”

oral solution and helps with the expansion of international markets.

(2) According to the definition of the International Association for Probiotics and Prebiotics

(ISAPP): a postbiotic is a preparation of inanimate microorganisms and/or their components

that confers a health benefit on the host (i.e., the human body)”.